Stroke Patient Management Tool (Standard, CM, Comprehensive) December 2014

Size: px
Start display at page:

Download "Stroke Patient Management Tool (Standard, CM, Comprehensive) December 2014"

Transcription

1 Patient ID: ADMIN Stroke Patient Management Tool (Standard, CM, Comprehensive) December 2014 Final clinical diagnosis related to stroke If No Stroke Related Diagnosis: ICD-9-CM Principal Diagnosis Code ICD-9-CM Other Diagnosis Codes Ο Ischemic Stroke Ο Transient Ischemic Attack (< 24 hours) Ο Subarachnoid Hemorrhage Ο Migraine Ο Seizure Ο Delirium.. ICD-9-CM Principal Procedure Code. ICD-9-CM Other Procedure Codes. ^What was the ICD-9-CM diagnosis code selected as the admitting diagnosis for this patient? When is the earliest documentation of comfort measures only? For patients discharged on or after 04/01/2011: What was the patient s discharge disposition on the day of discharge? If Other Health Care Facility. Bold Question = Required ^CSTK Comprehensive Stroke Element ^^GWTG only Comprehensive Stroke Element Admin Tab Ο Intracerebral Hemorrhage Ο Stroke not otherwise specified stroke related diagnosis Ο Elective Carotid Intervention only Ο Electrolyte or metabolic imbalance Ο Functional disorder Ο Other Ο Uncertain Ο Day 0 or 1 Ο Day 2 or after Ο Timing unclear t Documented/UTD 1 Home 2 Hospice Home 3 Hospice Health Care facility 4 Acute Care Facility 5 Other Health Care facility 6 Expired 7 Left Against Medical Advise/AMA 8 Not Documented or Unable to Determine (UTD) Ο Inpatient Rehabilitation Facility (IRF) Ο Intermediate Care facility (ICF) Ο Long Term Care Hospital (LTCH) Ο Skilled Nursing Facility (SNF) Ο Other ARRIVAL AND ADMISSION INFORMATION Admission Tab During this hospital stay, was the patient enrolled in a clinical trial in which patients with the same condition as the measure set were being studied (i.e. AMI, CAC, HF, PN, PR, SCIP, STK,VTE)? Was this patient admitted for the sole purpose of performance of elective carotid intervention? t in a healthcare setting Ο Outpatient healthcare setting Patient location when stroke Ο Another acute care facility Ο Stroke occurred after hospital arrival (in ED/Obs/inpatient) symptoms discovered Ο Chronic health care facility Ο ND or Cannot be determined How patient arrived at your hospital Ο EMS from home/scene Ο Private transportation/taxi/other from home/scene Was the patient an ED patient at the facility? ^Was the patient a direct admission to the hospital? Where patient first received Ο Emergency Department/ Urgent Ο Direct Admit, not care at your hospital Care through ED Advanced notification by EMS? /ND Ο N/A Arrival Date/Time: Ο Transfer from another hospital Ο Imaging suite Admit Date: Ο ND or Unknown Ο ND or Cannot be determined / / Stroke form -NOT FOR USE WITHOUT PERMISSION American Heart Association and Quintiles. Page 1

2 Not Admitted: Stroke Patient Management Tool (Standard, CM, Comprehensive) December 2014, not admitted, patient admitted as inpatient Where was the patient cared for and by whom? Check all that apply. Physician/Provider NPI: Reason Not Admitted: Neuro Admit Stroke Consult In Stroke Unit Ο Transferred from your ED to another acute care hospital Ο Discharged directly from ED to home or other location that is not an acute care hospital Ο Left from ED AMA Ο Died in ED Ο Discharged from observation status without an inpatient admission Ο Other Other Service Admission No Stroke Consult Not in Stroke Unit DEMOGRAPHICS Date of Birth: / / Age: Gender: Ο Male Ο Female Ο Unknown Hispanic Ethnicity: /UTD Specify Hispanic Ethnicity (see Coding Key) Race: (Check all that apply) Ο American Indian /Alaska Native Ο Asian Specify Asian (see Coding Key) Ο Black or African American Ο Native Hawaiian or Pacific Islander Specify Native Hawaiian or Pacific Islander (see Coding Key) Ο White Ο UTD Health Insurance Status: What is the patient's source of payment for this episode of care? Medicare Self Pay/No Insurance Ο Medicare n-medicare Medicaid Private/VA/Champus/Other Insurance Zip Code: - Homeless MEDICAL HISTORY None Atrial Fib/Flutter CAD/Prior MI Carotid Stenosis Previously known medical hx of: (Select all that apply) Ambulatory status prior to current event DIAGNOSIS & EVALUATION Symptom Duration if diagnosis of Transient Ischemic Attack (< 24 hours) Current Pregnancy (or up to 6 weeks post Depression Diabetes Mellitus partum) Drugs/Alcohol Abuse Dyslipidemia Family History of Stroke HF HRT Hypertension Migraine Obesity/Overweight Previous Stroke Previous TIA Prosthetic Heart Valve PVD Renal insufficiency chronic (SCr>2.0) Smoker Sickle Cell Sleep Apnea Ο Able to ambulate independently (no help from another person) w/ or w/o device Ο With assistance (from person) Ο Unable to ambulate Ο ND Ο Ο Less than 10 minutes minutes Had stroke symptoms resolved at time of presentation? Ο ND Initial NIH Stroke Scale /ND If Yes: Ο Actual Ο Estimated from the record Ο ND Ο > 60 minutes Ο ND Stroke form -NOT FOR USE WITHOUT PERMISSION American Heart Association and Quintiles. Page 2

3 Total Score (refer to web program for questions) ^What is the first NIHSS score obtained prior to or after hospital arrival? ^ Is there documentation that an initial ^Initial NIHSS Score Date and NIHSS score was done at this hospital? Time NIHSS score obtained from transferring facility: Weakness/Paresis Altered Level of Aphasia/Language Disturbance Initial exam findings Consciousness (Select all that apply) No neurological signs/symptoms Ambulatory status on admission Hemorrhagic Stroke Scales Ο Able to ambulate independently (no help from another person) w/ or w/o device Ο With assistance (from person) Ο Unable to ambulate Ο ND UTD Other neurological signs/symptoms ^^First Glasgow Coma Scale (GCS) Eye Verbal Intubated Motor Total GCS Intracerebral Hemorrhage (ICH) ^Was an initial ICH score done at this hospital? ^^If yes, ICH score: ^What is the date and time that the ICH score was first performed at this hospital? ^^FUNC Score (ICH) Subarachnoid Hemorrhage (SAH) ^Was an initial Hunt and Hess scale done at this hospital? ^^If yes, Hunt and Hess score: ^What is the date and time that the Hunt and Hess Scale was first performed at this hospital? ^^WFNS SAH Grading Scale MEDICATIONS PRIOR TO ADMISSION No medications prior to admission Antiplatelet or Anticoagulant Medication(s): /ND Antiplatelet aspirin aspirin/dipyridamole (Aggrenox) clopidogrel (Plavix) prasugrel (Effient) ticagrelor (Brilinta) ticlopidine (Ticlid) Other Antiplatelet Unfractionated heparin IV full dose LMW heparin warfarin (Coumadin) dabigatran (Pradaxa) argatroban desirudin (Iprivask) fondaparinux (Arixtra) rivaroxaban (Xarelto) apixaban (Eliquis) lepirudin (Refludan) Other Anticoagulant Antihypertensive /ND Cholesterol-Reducer /ND Diabetic medication /ND Antidepressant medication /ND SYMPTOM TIMELINE Time of Discovery Date/Time patient last known to be well? same as Last known well Anticoagulant Hospitalization Tab Date/Time of discovery of stroke symptoms? Stroke form -NOT FOR USE WITHOUT PERMISSION American Heart Association and Quintiles. Page 3

4 Comments BRAIN IMAGING Brain imaging completed at your hospital for this episode of care? MM/DD/YYYY only /ND Ο NC Date/Time Brain Imaging Initiated Interpretation of first brain image after symptom onset, done at any facility: ADDITIONAL TIME TRACKER See Target: Stroke Patient Time Tracker for data elements IV THROMBOLYTIC THERAPY IV t-pa initiated at this hospital? Documented Contraindications or Warnings for not initiating IV thrombolytic in the 0-3hr treatment window? Documented Contraindications or Warnings for not initiating IV thrombolytic in the 3-4.5hr treatment window? MM/DD/YYYY only Ο Hemorrhage Hemorrhage t Available Date/Time IV tpa initiated: Additional Warnings for patients treated between hrs (see Coding Key) If no documented contraindications 0-3hr 3-4.5hr or warnings, Hospital-Related or Delay in Patient Arrival Other Factors In-hospital Time Delay Delay in Stroke diagnosis If IV tpa was initiated greater than 60 minutes after hospital arrival, were Eligibility or Medical reason(s) documented as the cause for delay: Delay in stroke diagnosis If no documented eligibility or medical In-hospital time delay reason(s), Hospital Related or Other Equipment-related delay Reason(s) Other Reasons (see Coding Key) Reasons (see Coding Key) WAS OTHER THROMBOLYTIC/REPERFUSION THERAPY ADMINISTERED? IV tpa at an outside hospital? IA catheter-based treatment at this hospital? IA t-pa or MER Initiation Date/Time ^Is there documentation that the route of thrombolytic (t-pa) administration at this hospital was intra-arterial (IA)? ^Is there documentation that IA thrombolytic therapy was initiated at this hospital? ^Is there documentation in the medical record of the first pass of a mechanical reperfusion device to remove a clot occluding a cerebral artery at this hospital? ^What is the date & time of the First Pass? 0-3hr 3-4.5hr No IV access Other ^^Arterial puncture Date/Time ^Date/Time associated with IA thrombolytic therapy initiated for this patient at this hospital: Reasons (see Coding Key) Stroke form -NOT FOR USE WITHOUT PERMISSION American Heart Association and Quintiles. Page 4

5 ^^If MER treatment at this hospital, type of treatment: ^Proximal or distal occlusion ^What cerebral artery is occluded? Retrievable stent Other mechanical clot retriever device (not retrievable stent) Clot suction device Intracranial angioplasty, with or without permanent (non-retrieved stent) Cervical carotid angioplasty, with or without stent Other Ο The clot location is proximal Ο The clot location is distal Ο Neither proximal or distal are documented in reference to the location of the clot in the cerebral circulation or UTD from medical record documentation Ο Anterior cerebral artery (ACA) Ο A1 ACA Ο Anterior communicating artery Ο Cervical internal carotid artery (ICA) Ο Intracranial ICA Ο Middle cerebral artery (MCA) Ο M1 MCA Ο M2 MCA Ο M3/M4 MCA Ο Vertebral artery (VA) Ο Basilar artery (BA) Ο Posterior communicating artery (PCA) Ο Other cerebral artery branch/segment Ο The clinical location of the primary occluded vessel was not documented, OR unable to determine (UTD) from the medical record documentation ^Did the patient receive intravenous (IV) thrombolytic (t-pa) therapy at this hospital or a transferring hospital prior to receiving intra-arterial (IA) thrombolytic therapy or mechanical reperfusion therapy at this hospital? Investigational or experimental protocol for thrombolysis? ^^Thrombolysis in Cerebral Infarction (TICI) Post- Treatment Reperfusion Grade ^Is there a documented TICI reperfusion grade post treatment? ^^Surgical treatment for ICH at this hospital? ^^ If surgical treatment for ICH at this hospital, type: ^^ If ICH was evacuated, time from ictus to evacuation procedure start was: Additional Comments Related to Thrombolytics If yes, specify Ο Grade 0 Ο Grade 1 Ο Grade 2a Ο Grade 2b Ο Grade 3 Ο 1- A TICI reperfusion grade greater than or equal to 2b was documented post treatment IN-HOSPITAL TREATMENT AND COMPLICATIONS Complications of Thrombolytic Therapy Ο 2- A TICI reperfusion grade less than 2b was documented post treatment Ο 3 - A TICI reperfusion grade was not done post treatment, OR UTD from medical record documentation External Ventricular Drain (EVD) Endoscopic evacuation Conventional craniotomy and evacuation of clot under direct vision Stereotactic evacuation Hemicraniectomy without clot evacuation Fibrinolytic infusion via catheter Other (hours) Symptomatic intracranial hemorrhage <36 hours Life threatening, serious systemic hemorrhage <36 hours UTD Other serious complications No serious complications Stroke form -NOT FOR USE WITHOUT PERMISSION American Heart Association and Quintiles. Page 5

6 If bleeding complications occur in patient transferred after IV tpa: ^ What is the last NIHSS score documented prior to initiation of IV thrombolytic therapy at this hospital? ^What is the highest NIHSS score documented within 36 hours following initiation of IV (t-pa) thrombolytic therapy? ^ Was there a positive finding on brain imaging of parenchymal hematoma, SAH, and or IVH following IV or IA t- PA, OR mechanical endovascular reperfusion therapy initiation? ^^Results of positive brain image Ο Symptomatic hemorrhage detected prior to patient transfer Ο Symptomatic hemorrhage detected only after patient transfer UTD UTD ^Is there documentation that a procogulant reversal agent was initiated at this hospital? ^Is there documentation by a physician/apn/pa or pharmacist in the medical record of a reason for not administering a procoagulant reversal agent? ^^Date/Time procoagulant initiated Ο Unable to determine Ο N/A ^ What is the last NIHSS score documented prior to initiation of IA t-pa or MER at this hospital? ^What is the highest NIHSS score documented within 36 hours following IA t-pa or MER initiation? ^Date/Time of positive brain image UTD UTD PH2 (Parenchymal Hematoma Type 2) IVH (Intraventricular Hemorrhage) SAH (Subarachnoid Hemorrhage) RIH (Remote site of intraparenchymal hemorrhage outside the area of infarction) Other positive finding not listed above Not documented ^Is there documentation that nimodipine was administered at this hospital (SAH)? ^Is there documentation by a physician/apn/pa or pharmacist in the medical record of a reason for not administering nimodipine treatment? ^What is the date and time of nimodipine administration for this patient at this hospital? Dysphagia Screening Patient NPO throughout the entire hospital stay? /ND Was patient screened for dysphagia prior to any oral intake including water or medications? /ND Ο NC If yes, Dysphagia screening results: Ο Pass Ο Fail Ο ND Treatment for Hospital-Acquired Pneumonia Ο NC 5- Factor Xa Inhibitor 1- Low dose unfractionated heparin (LDUH) 6- Warfarin 2- Low molecular weight heparin (LMWH) VTE 7- Venous foot pumps (VFP) 3- Intermittent pneumatic compression devices Interventions 8- Oral Factor Xa Inhibitor (IPC) 9- Aspirin 4- Graduated compression stockings (GCS) A- None of the above or ND What date was the initial VTE prophylaxis administered after hospital admission? / / Is there documentation why VTE prophylaxis was not administered at hospital admission? Is there physician/apn/pa documentation why Oral Factor Xa Inhibitor was administered for VTE prophylaxis? Stroke form -NOT FOR USE WITHOUT PERMISSION American Heart Association and Quintiles. Page 6

7 Other Therapeutic Anticoagulati on Unfractionated heparin IV Dabigatran (Pradaxa) Argatroban Desirudin (Iprivask) Rivaroxaban (Xarelto) Apixaban (Eliquis) Lepirudin (Refludan) Other Anticoagulant Was DVT or PE documented? /ND Was antithrombotic therapy administered by the end of hospital day 2? /ND Ο NC If yes, select all that apply Antiplatelet Anticoagulant Is there documentation by a physician/advanced practice nurse/physician assistant (physician/apn/pa) or pharmacist in the medical record of a reason for not administering antithrombotic therapy by end of hospital day 2? MEASUREMENTS Total Lipids: ND Triglycerides: HDL: mg/dl LDL: Chol: mg/dl mg/dl mg/dl Lipids: NC A 1 C: Blood Glucose A % 1 C: ND (required if patient received IV tpa): mg/dl Too Low Too High Serum ^What is the first platelet count obtained prior to or after Creatinine: hospital arrival? UTD INR: NC ^Is there documentation in the medical record that the INR value performed closest to hospital arrival was greater than 1.4? ^^If initial INR > 1.4 and treated with procoagulant, Date/Time first INR 1.4 after treatment: No documented INR 1.4 after tx Vital Signs: Height: Weight: Heart Rate (beats per minute): Blood Pressure (required if patient received IV tpa): / mmhg (Systolic/Diastolic) Ο in Ο cm Ο lbs Ο kg Waist Circumference: Ο in Ο cm BMI: DISCHARGE INFORMATION Discharge Date/Time: GWTG Ischemic Stroke-Only Estimated Mortality Rate [Calculated in the PMT] GWTG Global Stroke Estimated Mortality Rate (Ischemic Stroke, SAH, ICH, Stroke NOS) [Calculated in the PMT] Modified Rankin Scale at Discharge /ND If Yes: Ο Actual Ο Estimated from the record Ο ND Total Score (refer to web program for questions) Ambulatory status at discharge Discharge Blood Pressure (Measurement closest to discharge) DISCHARGE DIAGNOSIS ICD-9 Other Diagnosis Codes Ο Able to ambulate independently (no help from another person) w/ or w/o device Ο With assistance (from person) Ο Unable to ambulate Ο ND / mmhg(systolic/diastolic). No Stroke or TIA Related ICD-9 Code Present DISCHARGE TREATMENTS Antithrombotic Therapy Prescribed? /ND Ο NC Discharge Tab Stroke form -NOT FOR USE WITHOUT PERMISSION American Heart Association and Quintiles. Page 7

8 approved in stroke Stroke Patient Management Tool (Standard, CM, Comprehensive) December 2014 If yes, Antiplatelet aspirin aspirin/dipyridamole (Aggrenox) clopidogrel (Plavix) ticlopidine (Ticlid) Dosage If NC, documented contraindications Frequency Anticoagulant Unfractionated heparin IV full dose LMW heparin warfarin (Coumadin) dabigatran (Pradaxa) argatroban fondaparinux (Arixtra) rivaroxaban (Xarelto) apixaban (Eliquis) lepirudin (Refludan) Dosage Allergy to or complications r/t antithrombotic Patient/Family refused Risk for bleeding or discontinued due to bleeding Frequency Serious side effect to medication Terminal illness/comfort Measures Only Other Prescribed? If yes, Other Antithrombotic(s) Medication: Dosage: Frequency: desirudin (Iprivask) ticagrelor (Brilinta) *contraindication in stroke and TIA prasugrel (Effient) 3 3. Other Persistent or Paroxysmal Atrial Fibrillation/Flutter If atrial fib/flutter or history of PAF documented, was patient discharged on anticoagulation? /ND Ο NC Allergy to or complication r/t warfarin or heparins Risk for falls If NC, documented reasons for Mental status Serious side effect to medication no anticoagulation Patient refused Terminal illness/comfort Measures Only Risk for bleeding or discontinued due to bleeding Antihypertensive Tx (Select all that apply) Cholesterol-Reducing Tx Statin Medication: (see Coding Key) None prescribed/nd None - contraindicated None prescribed/nd None - contraindicated ACE Inhibitors ARB Statin Fibrate Beta Blockers Ca++ Channel Blockers Niacin Absorption Inhibitor Diuretics Other anti-hypertensive med Other med Statin Total Daily Dose: Documented reason for not prescribing a statin medication at discharge? Intensive Statin Therapy /ND Ο NC New Diagnosis of Diabetes? Ο ND Basis for Diagnosis (Select all that apply): HbA1c Oral Glucose Tolerance Fasting Blood Sugar Test Other Stroke form -NOT FOR USE WITHOUT PERMISSION American Heart Association and Quintiles. Page 8

9 Diabetic Tx (Select all that apply): None prescribed/nd None contraindicated Other subcutaneous/injectable agents Anti-Smoking Tx /ND Ο NC Was the patient prescribed any antidepressant class of, SSRI, any other antidepressant class /ND medication at discharge? OTHER LIFESTYLE INTERVENTIONS Reducing weight and/or increasing activity recommendations /ND Ο NC TLC Diet or Equivalent /ND Ο NC Antihypertensive Diet /ND Ο NC Was Diabetes Teaching Provided? /ND Ο NC Insulin Oral agents STROKE EDUCATION Patient and/or caregiver received education and/or resource materials regarding all of the following: Check all as Yes: Stroke Warning Signs and Risk Factors for Stroke Symptoms How to Activate EMS for Stroke Need for Follow-Up After Discharge Their Prescribed Medication STROKE REHABILITATION Patient assessed for and/or received rehabilitation services during this hospitalization? Check all rehab services that patient received or was assessed for: POST DISCHARGE Patient received rehabilitation services during hospitalization Patient transferred to rehabilitation facility Patient referred to rehabilitation services following discharge Patient ineligible to receive rehabilitation services because symptoms resolved Patient ineligible to receive rehabilitation services due to impairment (i.e. poor prognosis, patient unable to tolerate rehabilitation therapeutic regimen) Go to Post Discharge Follow-Up Form within online tool (refer to web program for questions) ^What is the patients Modified Rankin Score (mrs) at 90 days post discharge? ^What is the date that the Modified Rankin Score (mrs) was obtained post discharge? / / OPTIONAL FIELDS Please do not enter any patient identifiers in this section Field 1 Field 2 Field 3 Field 4 Field 5 Field 6 Field 7 Field 8 Field 9 Field 10 Field 11 Field 12 Field 13 Additional Comments Field 14 Optional Fields Tab Administrative PMT used concurrently or retrospectively or combination? Ο Concurrently Ο Retrospectively Ο Combination Was a stroke admission order set used in this patient? Was a stroke discharge checklist used in this patient? Patient adherence contract/compact used? CORE MEASURE TAB (many elements are auto-populated within the online PMT) Core Measures Tab Check if patient is part of a sample First Name Last Name Stroke form -NOT FOR USE WITHOUT PERMISSION American Heart Association and Quintiles. Page 9

10 Race Stroke Patient Management Tool (Standard, CM, Comprehensive) December 2014 Ο Black or African American Ο American Indian or Alaska Native Zip Code - Homeless ΟAsia n Ο White Ο Native Hawaiian or Pacific Islander Ο UTD What is the patient's source of payment for this episode of care? Ο Medicare n-medicare HIC Number Was history of atrial fibrillation/flutter or current finding of atrial fibrillation/flutter documented in the medical record? Is there documentation that the patient was on a lipid-lowering medication prior to hospital arrival? Is there documentation that the date and time of last known well was witnessed or reported? What was the date and time at which the patient was last known to be well or at his or her baseline state of health? When is the earliest physician/apn/pa documentation of comfort measures only? Ο Day 0 or 1 Ο Day 2 or after Ο Timing unclear t Documented/UTD IV thrombolytic therapy initiated at this hospital? Did the patient receive IV or IA thrombolytic (t-pa) therapy at this hospital or within 24 hours prior to arrival? Documented reasons for not initiating IV thrombolytic? Was antithrombotic therapy administered by the end of hospital day 2? Was the LDL-cholesterol (LDL-c) measured within the first 48 hours or 30 days prior to hospital arrival? Was the patient's highest LDL-cholesterol (LDL-c) level greater than or equal to 100 mg/dl in the first 48 hours or within 30 days prior to hospital arrival? Discharge Date/Time Was antithrombotic therapy prescribed at hospital discharge? Is there documentation by a physician/advanced practice nurse/physician assistant (physician/apn/pa) or pharmacist in the medical record of a reason for not prescribing antithrombotic therapy at hospital discharge? Was anticoagulation therapy prescribed at hospital discharge? Is there documentation by a physician/advanced practice nurse/physician assistant (physician/apn/pa) or pharmacist in the medical record of a reason for not prescribing anticoagulation therapy at hospital discharge? Was a statin medication prescribed at discharge? Stroke Core Measure Additional Comments Stroke form -NOT FOR USE WITHOUT PERMISSION American Heart Association and Quintiles. Page 10

Stroke Patient Management Tool (Standard) March 2016

Stroke Patient Management Tool (Standard) March 2016 Patient ID: ADMIN Final clinical diagnosis related to stroke Ischemic Stroke Transient Ischemic Attack (< 24 hours) Subarachnoid Hemorrhage Bold Question = Required Intracerebral Hemorrhage Stroke not

More information

ACUTE STROKE REGISTRY (NJASR) VERSION 2.0) (Continued)

ACUTE STROKE REGISTRY (NJASR) VERSION 2.0) (Continued) New Jersey Department of Health ACUTE STROKE REGISTRY (NJASR) VERSION 2.0 A. DEMOGRAPHIC DATA *Hospital Type (1): 1=Primary 2=Comprehensive 3=Other *Hospital Code (2): *Hospital Transferred From Code (3):

More information

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Presented by Susan Haviland, BSN RN Senior Consult, Santa Rosa Consulting Meaningful Use Quality Measures Centers for Medicare and Medicaid Services

More information

Review of the Stroke and VTE Measure Sets

Review of the Stroke and VTE Measure Sets Review of the Stroke and VTE Measure Sets Vicky Agramonte, RN, MSN IPRO Quality Data Reporting and Improvement Project Presentation to NYS Hospitals January 29, 2013 The QIO Program CMS Leads a national

More information

AHA/ASA Ischemic Stroke Performance Measures

AHA/ASA Ischemic Stroke Performance Measures AHA/ASA Ischemic Stroke Performance Measures 1. Venous thromboembolism prophylaxis Percentage of patients with ischemic stroke who receive venous thromboembolism prophylaxis Numerator Hospital day 0 or

More information

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014 CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014 e 55 0495 2 Emergency Department (ED)- 1 Emergency Department Throughput Median time from

More information

Overview of the TJC/CMS VTE Core Measures

Overview of the TJC/CMS VTE Core Measures Overview of the TJC/CMS VTE Core Measures CMS Specification Manual 4.2 January 1, 2013 June 30, 2013 Victoria Agramonte, RN, MSN Project Manager, IPRO VTE Regional Learning Sessions NYS Partnership for

More information

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012 Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced

More information

Guidelines and Protocols

Guidelines and Protocols TITLE: HEAD TRAUMA PURPOSE: To provide guidelines for rapid, accurate assessment of the head and intracranial structures for traumatic injury and to plan and implement appropriate interventions for identified

More information

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for

More information

Level III Stroke Center Data Collection Requirements

Level III Stroke Center Data Collection Requirements Who? Level III Stroke Center Data Collection Requirements All LERN Level III Stroke Centers. LERN Level I and II Stroke Centers have reporting requirements to The Joint Commission or other Board approved

More information

FL PR Stroke Registry Goals

FL PR Stroke Registry Goals 20 th Annual Stroke Belt Consortium Meeting FL PR Goals To evaluate for disparities in stroke performance metrics by Race and ethnicity Geographic regions in Florida and Puerto Rico To investigate t the

More information

convey the clinical quality measure's title, number, owner/developer and contact

convey the clinical quality measure's title, number, owner/developer and contact CMS-0033-P 153 convey the clinical quality measure's title, number, owner/developer and contact information, and a link to existing electronic specifications where applicable. TABLE 20: Proposed Clinical

More information

Vascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial

Vascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial Vascular Quality Initiative - Carotid Artery Stent Last Name First Name Middle Initial Date of Birth Medical Record Social Security General Information Patient Data Zip/Postal Code Gender Male Female Ethnicity

More information

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7

More information

CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4

CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4 LAMC Department of Pharmacy Services: ANTICOAGULATION: Surgical Intervention Table 1: Classification of Surgical interventions according to bleeding risk t required to discontinue anticoagulation Dental

More information

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation

More information

Anticoagulation Therapy Update

Anticoagulation Therapy Update Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2

More information

High Risk Emergency Medicine

High Risk Emergency Medicine High Risk Emergency Medicine Minor Head Injuries in Patients on Oral Anticoagulants David Thompson, MD, MPH Assistant Professor Department of Emergency Medicine No relevant financial relationships to disclose

More information

Get With The Guidelines - Stroke PMT Special Initiatives Tab for Ohio Coverdell Stroke Program CODING INSTRUCTIONS Effective 10-24-15

Get With The Guidelines - Stroke PMT Special Initiatives Tab for Ohio Coverdell Stroke Program CODING INSTRUCTIONS Effective 10-24-15 Get With The Guidelines - Stroke PMT Special Initiatives Tab for Ohio Coverdell Stroke Program CODING INSTRUCTIONS Effective 10-24-15 Date and time first seen by ED MD: The time entered should be the earliest

More information

REMINDER: Please ensure all stroke and TIA patients admitted to hospital are designated as "Stroke Service" in Cerner.

REMINDER: Please ensure all stroke and TIA patients admitted to hospital are designated as Stroke Service in Cerner. ACUTE STROKE CLINICAL PATHWAY QEH/HH PCH KCMH Souris Western Stewart Memorial O'Leary PATIENT ID INCLUSION CRITERIA* All patients admitted to hosptial with a suspected diagnosis of acute ischemic stroke

More information

Critical Bleeding Reversal Protocol

Critical Bleeding Reversal Protocol Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy

More information

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG MED Hospitalist Stroke-TIA Vital Signs Vital Signs Q4H (DEF)* Q2H Q1H Vital Signs Orthostatic Activity Activity Bedrest, for 12 hours then Up ad lib (DEF)* Bedrest, for 24 hours then Up ad lib Up Ad Lib

More information

Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015

Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015 Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen

More information

Accreditation and Certification Guidelines

Accreditation and Certification Guidelines Accreditation and Certification Guidelines MARTIN GIZZI, MD, PHD, FAHA CHAIR, NJ NEUROSCIENCE INSTITUTE AT JFK CHAIR, NORTH EAST CEREBROVASCULAR CONSORTIUM (NECC) CHAIR, STROKE ADVISORY PANEL, NJDOH MEMBER,

More information

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

Rx Updates New Guidelines, New Medications What You Need to Know

Rx Updates New Guidelines, New Medications What You Need to Know Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact

More information

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow

More information

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin. To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation

More information

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding

More information

Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis

Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis Methodology: 8 respondents The measures are incorporated into one of four sections: Highly

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

3/3/2015. Patrick Cobb, MD, FACP March 2015

3/3/2015. Patrick Cobb, MD, FACP March 2015 Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict

More information

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE CASE REPORT: ACUTE STROKE MANAGEMENT 90 YEAR OLD WOMAN, PREVIOUSLY ACTIVE AND INDEPENDENT, CHRONIC ATRIAL FIBRILLATION,

More information

Acute Myocardial Infarction (the formulary thrombolytic for AMI at AAMC is TNK, please see the TNK monograph in this manual for information)

Acute Myocardial Infarction (the formulary thrombolytic for AMI at AAMC is TNK, please see the TNK monograph in this manual for information) ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Alteplase (Tissue Plasminogen Activator (t-pa)), Activase in the Treatment

More information

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix

More information

Cardiology Medications New Drugs, New Guidelines

Cardiology Medications New Drugs, New Guidelines Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 Cardiology Medications Objectives The attendee will understand Indications,

More information

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach. Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION

STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients

More information

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory

More information

Inpatient and Outpatient Manual Changes for 2015

Inpatient and Outpatient Manual Changes for 2015 Inpatient and Outpatient Manual Changes for 2015 Jill Daniel Project Manager Quality Measures Abstraction 15-036-AB GoToWebinar The Questions Chat Box Set your audio option Introduction to Data Dictionary

More information

Pulmonary Embolism Treatment Update

Pulmonary Embolism Treatment Update UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose

More information

PHYSICIAN ORDERS TRANSIENT ISCHEMIC ATTACK (TIA) OBSERVATION

PHYSICIAN ORDERS TRANSIENT ISCHEMIC ATTACK (TIA) OBSERVATION SCREENING- ABCD-2 Score The ABCD2 score is a risk assessment tool designed to improve the prediction of short-term stroke risk after a transient ischemic attack (TIA). Higher ABCD2 scores are associated

More information

Acute Ischemic Stroke with tpa

Acute Ischemic Stroke with tpa Admission/Condition/Diagnosis Admission: Admitting Physician Attending Physician Assign to Inpatient Status Transfer to Level of Care: Physician MUST document in notes the risk, severity, and skilled nursing

More information

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012 New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk

More information

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:

More information

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness

More information

ACUTE STROKE UNIT ORIENTATION

ACUTE STROKE UNIT ORIENTATION ACUTE STROKE UNIT ORIENTATION 2014 TEACHING YOUR STROKE PATIENTS ABOUT THEIR MEDICATION Please refer to Module 8: Secondary Stroke Prevention for additional information Blood Pressure Medication Angiotensin

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

Medicare & Medicaid EHR Incentive Program Meaningful Use Stage 1 Requirements Summary. http://www.cms.gov/ehrincentiveprograms/

Medicare & Medicaid EHR Incentive Program Meaningful Use Stage 1 Requirements Summary. http://www.cms.gov/ehrincentiveprograms/ Medicare & Medicaid EHR Incentive Program Meaningful Use Stage 1 Requirements Summary 2010 What are the Requirements of Stage 1 Meaningful Use? Basic Overview of Stage 1 Meaningful Use: Reporting period

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012

More information

2013 ACO Quality Measures

2013 ACO Quality Measures ACO 1-7 Patient Satisfaction Survey Consumer Assessment of HealthCare Providers Survey (CAHPS) 1. Getting Timely Care, Appointments, Information 2. How well Your Providers Communicate 3. Patient Rating

More information

Making the Case for CPG s Jean Luciano, MSN, RN, CNRN, SCRN, CRNP, FAHA Claranne Mathiesen, MSN, RN, CNRN, SCRN, FAHA

Making the Case for CPG s Jean Luciano, MSN, RN, CNRN, SCRN, CRNP, FAHA Claranne Mathiesen, MSN, RN, CNRN, SCRN, FAHA Making the Case for CPG s Jean Luciano, MSN, RN, CNRN, SCRN, CRNP, FAHA Claranne Mathiesen, MSN, RN, CNRN, SCRN, FAHA Disclosures Jeanie Luciano Genentech speakers bureau Claranne Mathiesen - none 1 Objective

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.

More information

Novel oral Anticoagulants, stroke and intracerebral hemorrhage

Novel oral Anticoagulants, stroke and intracerebral hemorrhage Novel oral Anticoagulants, stroke and intracerebral hemorrhage David Seiffge and Philippe Lyrer on behalf of the Basel Stroke Research Team: Leo Bonati, Gian Marco De Marchis, Stefan Engelter, Henrik Gensicke,

More information

SCRN Medication Review. Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center

SCRN Medication Review. Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center SCRN Medication Review Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center Objectives To explain the indications, contraindications, interaction, timing, dosing, side effects of: Thrombolytics

More information

Venous Thromboembolic Treatment Guidelines

Venous Thromboembolic Treatment Guidelines Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients

More information

The author has no disclosures

The author has no disclosures Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author

More information

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant

More information

ALBERTA PROVINCIAL STROKE STRATEGY (APSS)

ALBERTA PROVINCIAL STROKE STRATEGY (APSS) ALBERTA PROVINCIAL STROKE STRATEGY (APSS) Stroke Systems of Care Key Components APSS Pillar Recommendations March 28, 2007 1 The following is a summary of the key components and APSS Pillar recommendations

More information

Cardiology Medications New Drugs, New Guidelines

Cardiology Medications New Drugs, New Guidelines Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 CARDIOLOGY MEDICATIONS Objectives The attendee will understand Indications,

More information

Dorset Cardiac Centre

Dorset Cardiac Centre P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February

More information

Let s talk about: Stroke

Let s talk about: Stroke Let s talk about: Stroke February 20 th 2013 Laura Wilson Christine Stables Questions 1. Why is knowing about stroke important? 2. What exactly is a stroke and what are the symptoms? 3. What should I do

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,

More information

Patient and Hospital Characteristics Associated with Assessment For Rehabilitation During Hospitalization for Acute Stroke

Patient and Hospital Characteristics Associated with Assessment For Rehabilitation During Hospitalization for Acute Stroke Patient and Hospital Characteristics Associated with Assessment For Rehabilitation During Hospitalization for Acute Stroke Lead Author: Janet Prvu Bettger, ScD, FAHA Duke University ; janet.bettger@duke.edu

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia

More information

9/5/14. Objectives. Atrial Fibrillation (AF)

9/5/14. Objectives. Atrial Fibrillation (AF) Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

AnMed Health Disparities Dashboard

AnMed Health Disparities Dashboard AnMed Health Quick Facts 588 Bed Acute Care System Level II Trauma Center Emergency Department visits: 112,329 Admissions: 23,489 Active Medical Staff: 455 Employees: 3,511 Source : CY2013 Setting the

More information

Program Objectives. Why Use Anticoagulants? 6/5/2014

Program Objectives. Why Use Anticoagulants? 6/5/2014 Larry Reis RPh CGP FASCP Prepared June 2014 for NADONA REIS RXCARE CONSULTING Reisrxcare@comcast.net 1 Program Objectives Discuss complications of current anticoagulant Rx Identify risks of using anticoagulants

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

Clinical Practice Guideline for Anticoagulation Management

Clinical Practice Guideline for Anticoagulation Management Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.

More information

SOUTH EAST WALES CARDIAC NETWORK INTEGRATED CARE PATHWAY CARDIAC REHABILITATION MAY 2005

SOUTH EAST WALES CARDIAC NETWORK INTEGRATED CARE PATHWAY CARDIAC REHABILITATION MAY 2005 Name Address SOUTH EAST WALES CARDIAC NETWORK INTEGRATED CARE PATHWAY CARDIAC REHABILITATION MAY 2005 Ms / Miss / Mr / Mrs Addressograph Known as Telephone Number of Birth Hospital No. NHS No. Cardiac

More information

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis. DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

More information

Stroke Care First week

Stroke Care First week Stroke Care First week Florence Nightingale (1820 1910) Stroke Unit Dedicated personnel trained in stroke management Stepwise guidelines supported by explicit checklists Continuous monitoring available

More information

Medical Management of Ischemic Stroke: An Update. Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center

Medical Management of Ischemic Stroke: An Update. Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center Medical Management of Ischemic Stroke: An Update Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center Objectives Diagnostic evaluation and management of acute ischemic stroke. Inpatient management

More information

Traditional anticoagulants

Traditional anticoagulants TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University

More information

Anticoagulants in Atrial Fibrillation

Anticoagulants in Atrial Fibrillation Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives

More information

Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation

Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation On the following pages are a number of questions asking about the conditions under which you would prescribe anticoagulation

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

How To Treat Aneuricaagulation

How To Treat Aneuricaagulation Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent

More information

National Hospital Inpatient Quality Reporting Measures Specifications Manual

National Hospital Inpatient Quality Reporting Measures Specifications Manual National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes Version: 5.0 Release Notes Completed: March 9, 2015 Guidelines for Using Release Notes The Release Notes Version

More information

Inpatient Quality Reporting Program

Inpatient Quality Reporting Program Venous Thromboembolism 2015 Abstraction Guidance Questions and Answers Moderator: Candace Jackson, RN Inpatient Quality Reporting Support Contract Lead, HSAG Speakers: Denise Krusenoski, MSN, RN, CMSRN,

More information

East Kent Prescribing Group

East Kent Prescribing Group East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal

More information

Treatments to Restore Normal Rhythm

Treatments to Restore Normal Rhythm Treatments to Restore Normal Rhythm In many instances when AF causes significant symptoms or is negatively impacting a patient's health, the major goal of treatment is to restore normal rhythm and prevent

More information

New Oral Anticoagulants. How safe are they outside the trials?

New Oral Anticoagulants. How safe are they outside the trials? New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

More information

The Role of the Newer Anticoagulants

The Role of the Newer Anticoagulants The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention

More information

Stroke Coding Issues Presentation to: NorthEast Cerebrovascular Consortium

Stroke Coding Issues Presentation to: NorthEast Cerebrovascular Consortium Stroke Coding Issues Presentation to: NorthEast Cerebrovascular Consortium October 30, 2008 Barry Libman, RHIA, CCS, CCS-P President, Barry Libman Inc. Stroke Coding Issues Outline Medical record documentation

More information

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:

More information

Approximately 70-80% of all strokes are ischemic and 20-30% are hemorrhagic Hemorrhagic stroke is defined as an acute neurologic injury resulting from bleeding in the brain There are two distinct types

More information

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:

More information

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as

More information

International Hospital Inpatient Quality Measures

International Hospital Inpatient Quality Measures I-Acute Myocardial Infarction (I-AMI) I-AMI-1 Aspirin at Arrival Aspirin received within 24 hours of arrival to the hospital for patients having an acute myocardial infarction (AMI). I-AMI-2 Aspirin Prescribed

More information

HAAD JAWDA Quality KPI; waiting times. December 2015

HAAD JAWDA Quality KPI; waiting times. December 2015 HAAD JAWDA Quality KPI; waiting times December 2015 Page 1 of 13 Type: Waiting Time Indicator Indicator Number: WT001 Primary Care Appointment- Outpatient Setting Time to see a HAAD licensed family physician

More information

Service Specification Template Department of Health, updated June 2015

Service Specification Template Department of Health, updated June 2015 Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st

More information